Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities

Rituximab, a monoclonal antibody directed against B lymphocytes, has been found to be a therapeutic agent for severe, refractory autoimmune bullous diseases. However, a dosing schedule or treatment indication of rituximab has not yet been established.

[1]  E. Hodak,et al.  Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. , 2013, Journal of the American Academy of Dermatology.

[2]  H. Koga,et al.  Efficacy and safety of rituximab treatment in Indian pemphigus patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  P. Bernard,et al.  Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. , 2012, Journal of the American Academy of Dermatology.

[4]  R. Corona,et al.  Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. , 2012, Journal of the American Academy of Dermatology.

[5]  K. Propert,et al.  Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. , 2012, Archives of dermatology.

[6]  M. Jonkman,et al.  Low‐dose rituximab is effective in pemphigus , 2012, The British journal of dermatology.

[7]  G. Mufti,et al.  Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. , 2011, Journal of the American Academy of Dermatology.

[8]  D. Zillikens,et al.  Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. , 2011, Journal of the American Academy of Dermatology.

[9]  S. Kim,et al.  Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients , 2011, The British journal of dermatology.

[10]  V. Aoki,et al.  Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. , 2008, Journal of autoimmunity.

[11]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[12]  E. Bröcker,et al.  Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders , 2008, Clinical reviews in allergy & immunology.

[13]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[14]  E. Bröcker,et al.  Rituximab in autoimmune bullous diseases: mixed responses and adverse effects , 2007, The British journal of dermatology.

[15]  P. Itin,et al.  Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL , 2001, American journal of hematology.

[16]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Bystryn,et al.  The adjuvant therapy of pemphigus. An update. , 1996, Archives of dermatology.

[18]  D. Keskin,et al.  A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.